On the basis of the above findings, we propose that SDH-deficient GIST tumors may rely on exogenous lipids to provide energy for cellular metabolism, which could be interfered with by olverembatinib and contribute to the antitumor effects of the drug. Here, SDHB is linked to gastrointestinal stromal tumor.